Cencora OUTPH Insights

  1. Overcoming Regulatory, Pharmacovigilance, And Market Access Roadblocks To European Expansion 7/7/2026

    With 30 national HTA bodies, an EU-QPPV requirement, and MFN pricing now linking European reimbursement rates to U.S. drug prices, launching in Europe demands a coordinated global strategy.

  2. Competing Through Complexity: Models To Manage Mature Products 7/6/2026

    As patented drug revenues drop from 23% to just 10% by 2034, biopharma leaders need a clear framework for matching mature product strategy to their organization's operating model and risk appetite.

  3. Closing The Readiness Gap For CGTs In Community-Based Care 6/11/2026

    Only one in five eligible cell and gene therapy patients receives treatment. Expanding access into community hospitals requires overcoming significant operational and readiness barriers.

  4. How To Effectively Manage Local Affiliate Pharmacovigilance Outsourcing 5/12/2026

    Managing PV across dozens of markets strains even experienced safety teams. Learn about a framework that helps you maintain compliance, reduce risk, and scale confidently into new markets.

  5. Mid-Sized Pharma Optimizes Local Affiliate Safety Operations 5/12/2026

    Managing local affiliate PV strains any team. See how a mid-sized biopharma standardized ICSR processing across 94 countries, improved compliance tracking, and achieved centralized oversight.

  6. When CGT Supply Chains Break Down: 5 Operational Gaps That Put Patient Outcomes At Risk 4/22/2026

    Examine five of the most consequential gaps in CGT supply chain performance and learn what high-functioning teams do differently to protect patient outcomes before a failure occurs.

  7. Addressing A Critical Drug Shortage 4/20/2026

    A critical drug shortage demanded regulatory action, importation support, and patient program readiness. See how integrated QA, 3PL, and PSP capabilities delivered operational readiness in three months.

  8. Foreign Action Notification To Health Canada 4/20/2026

    Health Canada is tightening foreign action reporting expectations. MAHs need to understand what the updated draft guidance means for their compliance and monitoring processes now.

  9. Specialist PV Support Transforms Safety For Orphan Medicinal Products 4/17/2026

    Learn how a UK-based company developing two orphan-designated, centrally authorized therapies successfully navigated operational challenges after transitioning from a prior provider.

  10. Boosting Quality And Reducing Complexity With A Single-Provider PV Solution 4/17/2026

    Discover how a German biopharmaceutical company successfully managed growing global pharmacovigilance complexity across more than 2,300 marketing authorizations and a broad partner network.